日报更新时间：
周报更新时间：04-18 04:06
今开价：38.995
最高价：40.89
成交量：1259124.0
昨收价：39.96
最低价：38.715
最新价：40.135
中文名称：TG治疗
英文名称：TG Therapeutics
简介：TG Therapeutics, Inc.于1993年注册。TG医疗股份有限公司是一家生物制药公司，专注于创新、具有医学重要性治疗产品的收购、开发和销售，用于癌症和其他缺少治疗手段病症的治疗
电话：1-212-5544484
TG Therapeutics是一家生物制药公司，专注于B细胞恶性肿瘤和自身免疫性疾病的新型疗法的收购、开发和商业化。目前，该公司正在开发针对血液系统恶性肿瘤和自身免疫疾病的两种疗法。Ublituximab（TG-1101）是一种新型糖基化改造的单克隆抗体，其靶向成熟B淋巴细胞上发现的CD20抗原上的特异性和独特表位。TG Therapeutics还开发了umbralisib（TGR-1202），一种口服、每日一次的PI3K-delta抑制剂。Umbralisib独特地抑制CK1-epsilon，这可以使其克服与第一代PI3K-delta抑制剂相关的某些耐受性问题。Ublituximab和Umbralisib，或其被称为'U2'的组合，在血液系统恶性肿瘤患者的 III 期临床开发中，Ublituximab也在多发性硬化患者的 III 期临床开发中。此外，TG Therapeutics公司最近推出了抗PD-L1单克隆抗体TG-1501；其共价结合的Bruton酪氨酸激酶（Bruton Tyrosine Kinase，BTK）抑制剂TG-1701；以及其抗CD47 / CD19双特异性抗体TG-1801；目前进入 I 期开发阶段。TG Therapeutics, Inc. 与 LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated 和 Jubilant Biosys建立战略联盟关系。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2017-06-18 | Weiss (Michael S) | Chief Executive Officer | Buy | 834877 | -- |
| 2017-06-18 | Power (Sean A) | Chief Financial Officer | Sell | 30000 | 11.04 |
| 2017-06-18 | Weiss (Michael S) | Chief Executive Officer | Gift | 350000 | -- |
| 2017-06-15 | Charney (Laurence Neil) | Director | Buy | 15000 | -- |
| 2017-06-15 | Power (Sean A) | Chief Financial Officer | Sell | 29976 | 11.14 |
| 2017-06-15 | Kennedy (William James) | Director | Buy | 15000 | -- |
| 2017-06-15 | Schoenebaum (Mark) | Director | Buy | 15000 | -- |
| 2017-06-15 | Hume (Daniel) | Director | Buy | 15000 | -- |
| 2017-06-15 | Hoberman (Kenneth) | Director | Buy | 15000 | -- |
| 2017-06-15 | Echelard (Yann) | Director | Buy | 15000 | -- |
| 2017-04-10 | Kennedy (William James) | Director | Sell | 8548 | 10.27 |
| 2017-04-03 | Charney (Laurence Neil) | Director | Sell | 7000 | 11.17 |
| 2017-01-03 | Power (Sean A) | Chief Financial Officer | Sell | 8816 | 4.55 |
| 2016-12-31 | Weiss (Michael S) | Chief Executive Officer | Sell | 3381866 | -- |
| 2016-12-31 | Weiss (Michael S) | Chief Executive Officer | Buy | 2960000 | -- |
| 2016-12-31 | Weiss (Michael S) | Chief Executive Officer | Buy | 418371 | -- |
| 2016-12-29 | Weiss (Michael S) | Chief Executive Officer | Buy | 693750 | -- |
| 2016-12-29 | Power (Sean A) | Chief Financial Officer | Buy | 100000 | -- |
| 2016-08-31 | Weiss (Michael S) | Chief Executive Officer | Gift | 328764 | -- |
| 2016-07-05 | Kennedy (William James) | Director | Buy | 12459 | -- |
| 2016-07-05 | Charney (Laurence Neil) | Director | Buy | 12459 | -- |
| 2016-07-05 | Schoenebaum (Mark) | Director | Buy | 12459 | -- |
| 2016-07-05 | Echelard (Yann) | Director | Buy | 12459 | -- |
| 2016-07-05 | Hume (Daniel) | Director | Buy | 12459 | -- |
| 2016-07-05 | Hoberman (Kenneth) | Director | Buy | 12459 | -- |
| 2016-07-04 | Power (Sean A) | Chief Financial Officer | Sell | 50426 | 5.99 |
| 2016-04-17 | Power (Sean A) | Chief Financial Officer | Sell | 10000 | 10.12 |
| 2016-01-04 | Power (Sean A) | Chief Financial Officer | Sell | 22790 | 11.21 |
| 2015-12-30 | Power (Sean A) | Chief Financial Officer | Buy | 50000 | -- |
| 2015-12-30 | Weiss (Michael S) | Chief Executive Officer | Buy | 6723443 | -- |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Highland Capital Management LP | 878360 | 0.97% | 425000 | 93.74% | 2019-03-31 |
| BlackRock Fund Advisors | 2722269 | 3.00% | 15684 | 0.58% | 2019-07-31 |
| State Street Corporation | 3276966 | 3.61% | -1065652 | -24.54% | 2019-03-31 |
| Vanguard Group Inc | 3375742 | 3.72% | 1396074 | 70.52% | 2019-03-31 |
| SSGA Funds Management Inc | 3649372 | 4.02% | 72972 | 2.04% | 2019-07-31 |
| Bridger Management LLC | 4003481 | 4.41% | 211950 | 5.59% | 2019-03-31 |
| BlackRock Inc | 4437891 | 4.89% | -81440 | -1.80% | 2019-03-31 |
| Millennium Management LLC | 4905786 | 5.40% | 4786175 | 4001.45% | 2019-03-31 |
| RA Capital Management, LLC | 8198337 | 9.03% | -- | -- | 2019-03-31 |
| FMR Inc | 2402037 | 2.64% | -321400 | -11.80% | 2019-03-31 |
| Fidelity Management and Research Company | 2402037 | 2.64% | -321400 | -11.80% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 2337743 | 2.57% | -68 | -- | 2019-07-31 |
| Geode Capital Management, LLC | 928149 | 1.02% | -582261 | -38.55% | 2019-03-31 |
| Goldman Sachs Group Inc | 940656 | 1.04% | 178071 | 23.35% | 2019-03-31 |
| Northern Trust Investments Inc | 1268822 | 1.40% | 40818 | 3.32% | 2019-07-31 |
| Point72 Asset Management, L.P. | 1278900 | 1.41% | 1278900 | -- | 2019-03-31 |
| Calyon | 1307428 | 1.44% | -- | -- | 2019-03-31 |
| Cr¨?dit Agricole S.A. | 1307428 | 1.44% | -- | -- | 2019-03-31 |
| Opaleye Management Inc | 1366062 | 1.50% | 816062 | 148.37% | 2019-03-31 |
| Fidelity SelectCo, LLC | 2056141 | 2.26% | -221296 | -9.72% | 2019-07-31 |
| BlackRock Asset Management Canada Ltd | 1522046 | 1.68% | -111 | -0.01% | 2019-05-31 |
| venBio Select Advisor LLC | 4750000 | 5.23% | 549969 | 13.09% | 2018-12-31 |
| Great Point Partners LLC | 3000000 | 3.30% | 1050000 | 53.85% | 2018-12-31 |
| Northern Trust Corp | 801560 | 0.96% | -20879 | -2.54% | 2018-12-31 |
| Renaissance Technologies Corp | 875900 | 1.04% | 523400 | 148.48% | 2018-12-31 |
| Deutsche Bank AG | 824164 | 0.98% | 345477 | 72.17% | 2018-12-31 |
| Northern Trust Investments N A | 801560 | 0.96% | -20879 | -2.54% | 2018-12-31 |
| Two Sigma Investments LLC | 769011 | 0.92% | 582771 | 312.91% | 2018-12-31 |
| Franklin Resources Inc | 1892978 | 2.26% | -391499 | -17.14% | 2018-09-30 |
| Franklin Advisers, Inc. | 1883478 | 2.25% | -380299 | -16.80% | 2018-09-30 |
| Candriam Luxembourg | 692000 | 0.83% | 267000 | 62.82% | 2018-09-30 |
| Candriam Belgium | 692000 | 0.83% | 14000 | 2.06% | 2018-11-30 |
| PGIM Investments LLC | 938019 | 1.13% | -- | -- | 2018-11-30 |
| BlackRock Institutional Trust Company NA | 1656546 | 2.00% | 106022 | 6.84% | 2018-06-30 |
| UBS Asset Mgmt Americas Inc | 696792 | 0.84% | -254142 | -26.73% | 2018-06-30 |
| Wells Capital Management Inc. | 853825 | 1.03% | 853825 | -- | 2018-06-30 |
| Wells Fargo & Co | 888768 | 1.07% | 849233 | 2148.05% | 2018-06-30 |
| LFB Biotechnologies SA S U | 2614855 | 3.17% | -5000000 | -65.66% | 2018-07-06 |
| State Street Corp | 3712103 | 4.50% | 593842 | 19.04% | 2018-06-30 |
| Franklin Advisers Inc | 2263777 | 2.74% | -128520 | -5.37% | 2018-06-30 |
| Columbus Circle Investors | 747285 | 0.91% | -13745 | -1.81% | 2018-06-30 |
| UBS Group AG | 520596 | 0.67% | -354175 | -40.49% | 2018-05-31 |
| Goldman, Sachs & Co. | 349572 | 0.42% | 5544 | 1.61% | 2018-06-30 |
| Susquehanna Financial Group, LLLP | 324631 | 0.42% | -61125 | -15.85% | 2018-03-31 |
| J.P. Morgan Investment Management Inc | 285075 | 0.37% | -256725 | -47.38% | 2018-03-31 |
| Charles Schwab Investment Management Inc | 268174 | 0.35% | 1204 | 0.45% | 2018-03-31 |
| Susquehanna International Group, LLP | 324631 | 0.42% | -61125 | -15.85% | 2018-03-31 |
| Kennedy Capital Management Inc | 585439 | 0.80% | 164210 | 38.98% | 2017-12-31 |
| University of Notre Dame Du Lac | 302761 | 0.41% | 302761 | -- | 2017-12-31 |
| SENZAR ASSET MANAGEMENT, LLC | 863500 | 1.22% | -105800 | -10.92% | 2017-09-30 |
| Artal Group S A | 400000 | 0.57% | -100000 | -20.00% | 2017-09-30 |
| EAM Investors | 308120 | 0.44% | -5067 | -1.62% | 2017-09-30 |
| Hikari Power Ltd | 160000 | 0.23% | 100000 | 166.67% | 2017-09-30 |
| Columbia Mangmt Investment Advisers, LLC | 180451 | 0.26% | -96284 | -34.79% | 2017-09-30 |
| Credit Suisse First Boston (CSFB) | 224066 | 0.32% | 23514 | 11.72% | 2017-09-30 |
| Jennison Associates LLC | 1243995 | 1.76% | -106886 | -7.91% | 2017-09-30 |
| Baker Bros Advisors LP | 2003991 | 3.66% | -- | -- | -- |
| Eventide Asset Management, LLC | 537600 | 0.98% | -- | -- | -- |
| Stoneridge Investment Partners LLC | 289344 | 0.53% | -6138 | -2.08% | -- |
| New York State Common Retirement Fund | 223851 | 0.41% | -- | -- | -- |
| UBS Asset Management (UK) Ltd | 162870 | 0.30% | 8081 | 5.22% | -- |
| Teachers Retirement System Of The State Of Kentucky | 160700 | 0.29% | -- | -- | -- |
| Guggenheim Capital LLC | 159879 | 0.29% | -4334 | -2.64% | -- |
| BlackRock Advisors LLC | 148863 | 0.27% | -4671 | -3.04% | -- |
| LFB Biotechnologies, S.A.S. | 7614855 | 4.00% | 120619303 | 0.20% | 1999-11-30 |
| Michael S. Weiss | 8389376 | 4.00% | 132887716 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| iShares Micro-Cap ETF | 200078 | 0.22% | -- | -- | 2019-07-30 |
| SPDR | 3580868 | 3.94% | 70072 | 2.00% | 2019-07-31 |
| Vanguard Total Stock Market Index Fund | 2326090 | 2.56% | -- | -- | 2019-06-30 |
| iShares Russell 2000 ETF | 1715255 | 1.89% | 3355 | 0.20% | 2019-07-30 |
| Vanguard Extended Market Index Fund | 1003112 | 1.10% | 3881 | 0.39% | 2019-06-30 |
| Candriam Eqs L Biotechnology | 692000 | 0.76% | -- | -- | 2019-06-30 |
| iShares Russell 2000 Growth ETF | 650357 | 0.72% | 12538 | 1.97% | 2019-07-30 |
| UBS (Lux) EF Biotech (USD) | 564287 | 0.62% | -- | -- | 2019-04-30 |
| Highland Global Allocation Fund | 387600 | 0.43% | -- | -- | 2019-06-30 |
| State Street Russell Small/Mid Cap | 275039 | 0.30% | -- | -- | 2019-06-30 |
| State Street Russell Small Cap | 263151 | 0.29% | -- | -- | 2019-06-30 |
| JPMorgan US Small Company Fund | 208125 | 0.23% | -11900 | -5.41% | 2019-06-30 |
| Direxion Daily S&P Biotech Bull 3X Shrs | 208434 | 0.23% | 56548 | 37.23% | 2019-04-30 |
| NexPoint Strategic Opportunities Fund | 210000 | 0.23% | -- | -- | 2019-03-31 |
| Schwab US Small-Cap ETF | 216041 | 0.24% | 184 | 0.09% | 2019-07-31 |
| NT R2000 Index Fund - NL | 237282 | 0.26% | 1424 | 0.60% | 2019-06-30 |
| Fidelity | 256252 | 0.28% | 32448 | 14.50% | 2019-04-30 |
| NT R2000 Growth Index Fund - Non-Lending | 259924 | 0.29% | -9271 | -3.44% | 2019-06-30 |
| Vanguard Health Care Index Fund | 197260 | 0.22% | 23120 | 13.28% | 2019-05-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 1322274 | 1.46% | -2223 | -0.17% | 2019-05-30 |
| NT R2000 Growth Index Fund - Lending | 183331 | 0.21% | 592 | 0.32% | 2019-03-31 |
| Interfund Equity USA | 197117 | 0.24% | -102883 | -34.29% | 2019-02-28 |
| Northern Trust Russell 2000 Index DC NL | 164875 | 0.20% | 9093 | 5.84% | 2019-02-28 |
| The Vanguard - Russell 2000 Grwth Idx CF | 111946 | 0.13% | -- | -- | 2019-01-31 |
| Schwab Small Cap Index Fund | 118841 | 0.14% | -- | -- | 2019-01-31 |
| Invesco Raymond James SB-1 Equity ETF | 140954 | 0.17% | -- | -- | 2018-10-12 |
| AXA 2000 Managed Volatility Portfolio | 102173 | 0.12% | -- | -- | 2018-12-31 |
| Fidelity Advisor | 221296 | 0.27% | -- | -- | 2018-11-30 |
| Franklin Small Cap Growth Fund | 253375 | 0.31% | -333368 | -56.82% | 2018-10-31 |
| Franklin Biotechnology Discovery Fund | 347400 | 0.42% | -156600 | -31.07% | 2018-10-31 |
| Wells Fargo Discovery Fund | 574500 | 0.69% | -- | -- | 2018-08-31 |
| PGIM Jennison Health Sciences Fund | 938019 | 1.13% | -- | -- | 2017-11-30 |
| iShares Russell 2000 Growth | 563937 | 0.59% | -544 | -0.10% | 2018-09-12 |
| Fidelity Spartan | 115447 | 0.14% | -- | -- | 2018-07-31 |
| Vanguard Health Care ETF | 123905 | 0.15% | 1062 | 0.86% | 2018-07-31 |
| State Street Russell Small/Mid Cap Idx Fd Cl I | 153665 | 0.23% | 41364 | 36.83% | 2017-06-30 |
| Vanguard Total Stock Mkt Idx | 1471915 | 1.78% | -- | -- | 2018-07-31 |
| Franklin Small Cap Growth A | 842443 | 1.02% | -- | -- | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 806305 | 0.98% | 23300 | 2.98% | 2018-07-31 |
| Wells Fargo Discovery Admin | 574500 | 0.70% | -- | -- | 2018-07-31 |
| Franklin Biotechnology Discovery A | 504000 | 0.61% | -- | -- | 2018-07-31 |
| JPMorgan US Small Company Instl | 246300 | 0.30% | 4800 | 1.99% | 2018-07-31 |
| NexPoint Credit Strategies Fund | 210000 | 0.25% | -- | -- | 2018-06-30 |
| iShares Micro-Cap | 157240 | 0.16% | -- | -- | 2018-09-12 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 145078 | 0.18% | -385 | -0.26% | 2018-07-31 |
| Highland Global Allocation A | 122600 | 0.15% | -- | -- | 2018-06-30 |
| Schwab Small Cap Index | 110350 | 0.14% | 17700 | 19.10% | 2018-06-30 |
| BlackRock Extended Equity Market K | 102225 | 0.13% | 27895 | 37.53% | 2018-06-30 |
| CREF Stock R1 | 87742 | 0.11% | -- | -- | 2018-04-30 |
| BioShares | 91951 | 0.12% | -- | -- | 2018-06-14 |
| Guggenheim Raymond James SB-1 Equity ETF | 87865 | 0.12% | -- | -- | 2018-06-06 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 83701 | 0.11% | -- | -- | 2018-03-31 |
| The Vanguard Russell 2000 Growth Index | 81786 | 0.11% | -- | -- | 2018-03-31 |
| Pru Ret Small Cap Value/Kennedy SP | 130237 | 0.18% | 33626 | 34.81% | 2017-12-31 |
| VP Partners Small Cap Growth 2 | 95639 | 0.14% | -- | -- | 2018-01-31 |
| Prudential Jennison Health Sciences A | 938019 | 1.33% | -- | -- | 2017-11-30 |
| Eventide Healthcare & Life Sciences A | 537600 | 0.98% | -- | -- | -- |
| AXA 2000 Managed Volatility K | 57935 | 0.11% | -- | -- | -- |
| JNL/Mellon Capital Healthcare Sector B | 33002 | 0.06% | -- | -- | -- |
| Nationwide HighMark Sm Cp Core A | 54442 | 0.10% | 1150 | 2.16% | -- |
| SPDR® S&P Biotech ETF | 2007546 | 4.20% | 13076 | 0.70% | 2015-11-19 |
| Fidelity Advisor® Biotechnology Fund | 1328407 | 2.50% | 54752 | 4.30% | 2015-09-30 |
| iShares Russell 2000 (AU) | 560585 | 1.20% | -708 | -0.10% | 2015-11-19 |
| Eventide Healthcare & Life Sciences Fund | 271100 | 0.50% | 88100 | 48.10% | 2015-06-30 |
| Fidelity Spartan® Extended Mkt Indx Fd | 143128 | 0.30% | -- | -- | 2015-09-30 |
| CREF Stock Account | 91244 | 0.20% | -- | -- | 2015-09-30 |
| Alger Health Sciences Fund | 80450 | 0.20% | -- | -- | 2015-08-31 |
| Fidelity® Select Biotechnology Portfolio | 4629568 | 8.80% | 230332 | 5.20% | 2015-09-30 |
| Michael Sean Weiss | Mr. Michael S. Weiss is a Chairman at National Holdings Corp., a Chairman at Checkpoint Therapeutics, Inc., a Chairman at Mustang Bio, Inc., an Executive Chairman at IASO Pharma, Inc., a Partner at Opus Point Partners Management LLC, a Partner & Portfolio Manager at Opus Point Partners LLC and an Executive Chairman, President & CEO at TG Therapeutics, Inc. He is on the Board of Directors at Avenue Therapeutics, Inc., Caelum Biosciences, Inc., Cellvation, Inc., Cyprium Therapeutics, Inc. and Helocyte, Inc. Mr. Weiss began his professional career as a lawyer at Cravath, Swaine & Moore. From 1993 through 1999, he worked with Dr. Rosenwald in managing Paramount Capital/Aries Funds. In 1999, he founded Access Oncology which was later acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004. Mr. Weiss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. |
|---|---|
| Mark J. Schoenebaum | Dr. Mark J. Schoenebaum, MD, is an Independent Director at TG Therapeutics, Inc. He is on the Board of Directors at Health Sciences Acquisitions Corp. and TG Therapeutics, Inc. Dr. Schoenebaum was previously employed as a Fundamental Research Analyst by Evercore Group LLC, a Senior Managing Director by International Strategy & Investment Group LLC, a Managing Director by Deutsche Bank Securities, Inc., a Senior Research Analyst by Bear, Stearns & Co., Inc., an Analyst by Alexandra Investment Management LLC, a Senior Research Analyst by Piper Jaffray & Co., and a Senior Analyst by CIBC World Markets Corp. (Old). He received his undergraduate degree from Indiana University and a doctorate degree from The Johns Hopkins University School of Medicine. |
| William James Kennedy | William James Kennedy is on the board of TG Therapeutics, Inc. In his past career he held the position of Vice President-Regulatory Affairs at Zeneca Corp. and Associate Research Professor at Yale School of Medicine. Dr. Kennedy received an undergraduate degree from Siena College, a graduate degree from Clark University and a doctorate from State University of New York at Buffalo. |
| Laurence N. Charney | Mr. Laurence N. Charney is an Independent Director at Kenon Holdings Ltd., an Independent Director at TG Therapeutics, Inc., a Member at New York State Society of Certified Public Accountants and a Member at The American Institute of Certified Public Accountants. He is on the Board of Directors at Kenon Holdings Ltd. and TG Therapeutics, Inc. Mr. Charney was previously employed as an Independent Director by IC Power Ltd. (Singapore), an Independent Director by Pacific Drilling SA, an Independent Director by Iconix Brand Group, Inc., a Director-Americas by Conflict Management Group, and a Senior Audit Partner by Ernst & Young LLP. He also served on the board at Mrs. Fields' Original Cookies, Inc., Pure Biofuels Corp., XTL Biopharmaceuticals Ltd. and Marvel Entertainment LLC. He received his undergraduate degree from Hofstra University and an MBA from Columbia University. |
| Jenna A. Bosco | Presently, Jenna A. Bosco is Senior Vice President-Corporate Communications at TG Therapeutics, Inc. In her past career she held the position of Principal at Opus Point Partners Management LLC. Ms. Bosco received an undergraduate degree from Robert H. Smith School of Business. |
| Jenna A. Bosco | Presently, Jenna A. Bosco is Senior Vice President-Corporate Communications at TG Therapeutics, Inc. In her past career she held the position of Principal at Opus Point Partners Management LLC. Ms. Bosco received an undergraduate degree from Robert H. Smith School of Business. |
| Sean A. Power | Currently, Sean A. Power is Chief Financial Officer, Secretary & Treasurer for TG Therapeutics, Inc. He is also Member of The American Institute of Certified Public Accountants. In his past career he occupied the position of Chief Financial Officer for Opus Point Partners Management LLC, Associate of UHY Advisors, Inc., Senior Associate at KPMG, Inc. and Controller at Keryx Biopharmaceuticals, Inc. He received an undergraduate degree from Siena College. |
| Kenneth Hoberman | Presently, Kenneth Hoberman is Chief Operating Officer & Secretary at Stemline Therapeutics, Inc. Mr. Hoberman is also on the board of TG Therapeutics, Inc. In the past he held the position of Vice President-Business Development of Keryx Biopharmaceuticals, Inc. Mr. Hoberman received an undergraduate degree from Boston University. |
| Robert Niecestro | Dr. Robert Niecestro is Vice President-Clinical & Regulatory at Axsome Therapeutics, Inc. and Executive Vice President-Clinical & Regulatory at TG Therapeutics, Inc. Dr. Niecestro was previously employed as Vice President-Clinical Development by Andrx Laboratories, Inc., Senior Director-Clinical Development by Eisai, Inc., Vice President-Clinical & Regulatory Affairs by Keryx Biopharmaceuticals, Inc., and Director-Clinical Operations by Organon USA, Inc. He received his undergraduate degree from the University of Illinois. |
| Yann Echelard | Yann Echelard is on the board of TG Therapeutics, Inc., LFB USA, Inc. and Hema Biologics. In the past he was President, Chief Executive Officer & Director at rEVO Biologics, Inc., Vice President-Research & Development at GTC Biotherapeutics UK Ltd. and Principal at rEVO Biologics, Inc. He received a doctorate from the University of Montr�0�1�0�8al. |
| Daniel Hume | Daniel Hume is on the board of TG Therapeutics, Inc., National Holdings Corp. and Stemline Therapeutics, Inc. and Member of New York State Bar Association, Partner at Kirby Mcinerney LLP and Member of Supreme Court of the United States. He received an undergraduate degree from State University of New York at Albany and a graduate degree from Columbia Law School. |
| Adam Waldman | Adam Waldman is Chief Commercial Officer of TG Therapeutics, Inc. In the past he held the position of Head-Haematology & Oncology Marketing at Celgene Corp. Mr. Waldman received an MBA from the University of Rochester Simon Business School and an undergraduate degree from Rutgers State University of New Jersey. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论